Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cell therapy trial targets Hard-to-Treat brain and nerve disorders

NCT ID NCT07021209

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times

Summary

This early-stage study tests a new treatment called GT719 for people with severe neurological autoimmune diseases that have not responded to standard therapies. The treatment uses specially designed cells to target the immune system's attack on the brain and nerves. The study will enroll 30 adults to check safety and see if the treatment helps control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROLOGICAL AUTOIMMUNE DISEASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.